Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019)
Enanta Pharmaceuticals' (ENTA) quarterly Non-Current Deffered Revenue came in at $900000.0 in Q3 2019, up 51.77% YoY from $593000.0 in Q3 2018, and down 2.49% on a QoQ basis from $923000.0 in Q2 2019.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $900000.0 in Q3 2019.
- Quarterly Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $900000.0 (up 51.77% YoY) and the FY2019 annual result came in at $900000.0, up 51.77% from the prior year.
- Non-Current Deffered Revenue fell to $900000.0 in Q3 2019, from $923000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $923000.0 in Q2 2019 to a low of $161000.0 in Q1 2015.
- A 5-year average of $650789.5 and a median of $674000.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue jumped 322.22% — and 2018, when it retreated 14.06%.
- Tracing ENTA's Non-Current Deffered Revenue over 5 years: stood at $646000.0 in 2015, then rose by 8.51% to $701000.0 in 2016, then retreated by 6.7% to $654000.0 in 2017, then climbed by 3.06% to $674000.0 in 2018, then soared by 33.53% to $900000.0 in 2019.
- The last three Non-Current Deffered Revenue figures came in at $900000.0 (Q3 2019), $923000.0 (Q2 2019), and $842000.0 (Q1 2019), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Enanta Pharmaceuticals | 404.93 Mn | 215.43 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 900,000.00 |
| Jun 30, 2019 | 923,000.00 |
| Mar 31, 2019 | 842,000.00 |
| Dec 31, 2018 | 674,000.00 |
| Sep 30, 2018 | 593,000.00 |
| Jun 30, 2018 | 611,000.00 |
| Mar 31, 2018 | 632,000.00 |
| Dec 31, 2017 | 654,000.00 |
| Sep 30, 2017 | 676,000.00 |
| Jun 30, 2017 | 711,000.00 |
| Mar 31, 2017 | 706,000.00 |
| Dec 31, 2016 | 701,000.00 |
| Sep 30, 2016 | 696,000.00 |
| Jun 30, 2016 | 682,000.00 |
| Mar 31, 2016 | 664,000.00 |
| Dec 31, 2015 | 646,000.00 |
| Sep 30, 2015 | 628,000.00 |
| Jun 30, 2015 | 265,000.00 |
| Mar 31, 2015 | 161,000.00 |
| Dec 31, 2014 | 153,000.00 |